Board of Directors

Ms. Maria Gobbi (Non-Executive Chairperson)

Ms. Maria Gobbi holds a degree in 'Chemical Engineering' from the University of Politecnico, Milan, Italy. She has experience of three decades in pharmaceutical industry at international level.

Ms. Gobbi is Non-Executive Chairperson of the Company and immediate past Managing Director of Fresenius Kabi Oncology Limited. She is also the Executive Vice President, BU-API. Prior to her association with Fresenius Kabi, she was the General Manager of Antibioticos Spain and VP of Sales and Marketing of Alpharma Aps, a USA based company located in Scandinavian Countries and manufacturing mainly Antibiotics, both APIs and Finished Products.

In her illustrious professional career, she has handled many critical assignments related to accessing new markets, diversifying customer's portfolio, optimizing manufacturing set-up, driving the companies toward FDA approved status etc. She has been also playing a key role in the revival plan for Kalyani facility of the Company.

Dr. Michael Schönhofen (Non-Executive Director)

Dr. Michael Schönhofen holds a Doctorate degree from Gesellschaft für Schwerionenforschung, Darmstadt, Germany and College of Advanced Technology, Darmstadt. Dr. Schönhofen has been associated with the Fresenius group since 1991 in various functions and responsibilities. He is currently holding the position of President, Pharmaceuticals and Devices Division and is also a Member of the Management Board of Fresenius Kabi AG, Germany.

Mr. Rakesh Bhargava (Non- Executive Director)

Mr Bhargava has almost three decades of rich experience in the pharmaceutical industry. He was the Non-Executive Chairman of Fresenius Kabi Oncology Limited until April, 2018. Earlier, he was the Executive Vice President, Region South-East Asia and a member of the Management Team of Fresenius Kabi Asia-Pacific. Simultaneously he was Managing Director & CEO of Fresenius Kabi India Private Limited which is another Fresenius Kabi subsidiary in India located at Pune. He has served as a member of the Board of Directors of Fresenius Kabi Thailand, Fresenius Kabi Singapore, Fresenius Kabi Malaysia, and as the Legal Supervisor of Fresenius Kabi Taiwan. Prior to assuming a position in Fresenius Kabi, he was the Managing Director of Lupin Chemicals (Thailand) Ltd based at Bangkok. He has also worked with Imperial Chemical Industry plc U.K.’s Pharmaceutical Business (predecessor of Astra Zeneca) in the capacity of General Manager for India.

Mr Bhargava is a former member of the Executive Committee of Organization of Pharmaceutical Producers of India (OPPI) and Chairman of its Legal Committee. He has been a member of CII’s National Committee on Drugs and Pharmaceuticals for more than 10 years, and is a former President of "The Pharmaceutical Form-Fill-Seal Association of India". He is on the Advisory Board of Pharmabiz, and was a Board Member of the Centre for Research on Nutrition Support Systems (CRNSS).

Mr. Rakesh Bhargava is an MBA from Indian Institute of Management, Ahmedabad and a Bachelor of Technology [Chemical Engineering] from Indian Institute of Technology, Kanpur

Steffen Roser (Non - Executive Director)

Mr. Steffen Roser obtained his Master's Degree in Business Administration from the Frankfurt University, Germany in 1988.

In year 1989, he started his professional career as a Controller with Procter & Gamble. He joined Fresenius Group in year 1994 as a Controller Corporate and since then has handled many critical assignments within the Fresenius group at different positions. Currently he is acting as the CFO of Pharmaceutical and Devices Division at Fresenius Kabi, Germany.

Mr. Karsten Lerch (Non - Executive Director)

Mr. Karsten Lerch holds a degree in Economics from Eberhard-Karls-University of Tübingen, Germany.

Mr. Lerch has more than 20 years of rich experience at international level. He started his professional career as a business consultant with GMO Management Consulting Group in Düsseldorf with a focus on SAP and Controlling projects.

He has been associated with Fresenius Group since March 2014 and worked as the Director Compliance & Process Excellence at Fresenius Kabi Deutschland GmbH, Pharmaceuticals and Devices Division.

He has been appointed as the Non-Executive Director of the Company w.e.f. January 1, 2018, prior to which he was holding the position of Whole-time Director & CFO, since January 1, 2016.

Mr. Rajiv Lochan Jain (Non - Executive Independent Director)

Mr. Rajiv Lochan Jain is a Chemical Engineer from IIT Kharagpur and an MBA from the Peter T Paul College of Business and Economics, UNH, USA.

Mr. Jain was a member on the Board of ICI India Limited for over 12 years and the Managing Director from April 2003 to May 2009. Mr. Jain successfully led the portfolio reshaping of ICI India from a diversified chemical Company to a focused and fastest growing player in the Paints business. Mr. Jain was also the Chairman of both ICI's Research Company in India and the joint-venture company of ICI and Orica, Australia.

Currently, he advises global and local companies on their entry and growth strategies for India and serves on the Board of Goodyear India Limited and Gujarat Alkalies and Chemicals Limited.

Dr. Uday Chandrashekhar Shetty (Non-Executive Independent Director)

Dr. Uday Chandrashekhar Shetty holds a Ph.D (Tech) from the Mumbai University. He is a Pharmaceutical professional with over 30 years of experience in Quality Management, Product Development, Technology Transfers and Manufacturing Operations.

He has vast experience in EHS, Engineering, Purchase, Finance and Marketing/ Sales for CRO’s. Previously, he has served as the co-founder Director of a Contract Research Organization. He has also gained unparallel experience while working with leading pharmaceutical companies like Janssen, Burroughs Wellcome and American Cyanamid.

Presently, Dr. Shetty serves as the Director of “GMP Education” a non-profit organization which imparts free online Pharmaceutical Education. Additionally, he also serves as the Chairman of the International Society of Pharmaceutical Engineering, India affiliate and as a member of the Technical Committee of Indian Drug Manufacturer’s Association.

Mr. Arvind Kumar Sharma (Managing Director)

Mr. Arvind Kumar Sharma has over 30 years of experience in the manufacturing of Bulk Pharmaceutical Chemicals (APIs) & Biopharmaceuticals. Mr. Sharma completed his B. Tech in Biochemical Engineering from H.B.T.I., Kanpur and M. Tech in Biotechnology from Jadavpur University, Calcutta. He has been associated with the Company since June, 2013 and has been efficiently leading the Kalyani plant operations since then. He has also been leading operations of the Baddi plant since July, 2017.

During his rich experience, he has worked in leadership positions with specialist pharmaceutical companies such as Arch Pharmalabs Limited, Vitalife Laboratories, Concord Biotech Limited and KDL Biotech Limited. His area of expertise spans across manufacturing excellence, operations improvement, planning and systems development and workflow planning.

Mr. Nikhil Kulshreshtha (Director & Secretary)

Mr. Nikhil Kulshreshtha is a member of the Institute of Company Secretaries of India (ICSI). He has also attended management and leadership programs from national and international management institutions like IIM (Ahmadabad), NUS, Singapore etc. Mr. Kulshreshtha has overall 29 years of professional experience and has been associated with the Company since the year 2007. During this period, he has worked in different capacities with large Indian conglomerates like Bharti Airtel, HCL and DLF, handling secretarial, legal, commercial, accounts and administrative functions. In his professional career, he has acquired extensive hands on experience in handling Mergers & Acquisition, Legal Due Diligence, Integration, IPO's & ESOP formulation and Statutory Compliances etc.

Mr. Zankar Himatlal Pandya (Chief Financial Officer)

Mr. Zankar Himatlal Pandya holds a Degree in Bachelor of Business Administration (BBA) from Maharaja Sayajirao University (Baroda, India) and has also completed Master of Business Administration (MBA) from University of Wollongong (Wollongong), Australia.

Mr. Zankar Himatlal Pandya is also a CPA ("Certified Practising Accountant") professional from Australia, having a diverse work experience of over 15 years locally in India and at an international level. He has gained this experience in various roles involving functions analysis related to Sales and Marketing, Supply Chain activities, Financial Consolidation, Financial reporting, Controlling of Overheads, manufacturing activities and Australia and New Zealand Taxation and Financial Management.

He commenced his Career as ‘Commissions Analyst’ with MLC, a National Group Company, North Sydney in 2004 and subsequently moved on to work with Commander Communications Ltd., Australia. This was followed by an enriching stint with Reckitt Benckiser, Australia as Commercial Analyst & Reckitt Benckiser India as Finance Manager.

He joined Fresenius Kabi Oncology Ltd. in June, 2015 as Deputy General Manager- Finance & Accounts looking after Controlling, Finance & Accounts and Taxation activities at PU-Baddi. In 2017, he was promoted to General Manager-Controlling taking the overall responsibilities of consolidating Controlling function for FKOL whilst retaining the responsibilities for PU-Baddi.

Before appointment as CFO, he was holding the position of General Manager-Controlling and the responsibilities of Deputy CFO.



© All Copyright Reserved | Fresenius Kabi Oncology Limited 2012
This site is best viewed with a resolution of 1024x768 (or higher) and supports Microsoft Internet Explorer 8.0+ and Firefox 3.0+